We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Plasma Matrix Metalloproteinase-1 as a Prognostic Biomarker in Oral Cavity Squamous Cell Carcinoma.
- Authors
Tsai, Tsung-You; Kao, Huang-Kai; Huang, Yenlin; Chang, Ya-Ting; Young, Chi-Kuang; Hung, Shao-Yu; Chang, Yu-Sun; Yu, Jau-Song; Chang, Kai-Ping
- Abstract
Purpose: Plasma matrix metalloproteinase-1 (MMP-1) is a collagenase encoded by the MMP-1 gene. However, the prognostic value of plasma MMP-1 levels in oral cavity squamous cell carcinoma (OSCC) has yet to be elucidated. The study is the first to use a cohort of OSCC patients to assess the association of plasma MMP-1 levels with clinicopathological factors/survival outcomes in OSCC patients. Patients and Methods: A total of 677 patients were retrospectively enrolled, including 276 oral potentially malignant disease (OPMD) and 401 OSCC patients from 2013 to 2021. Pretreatment plasma MMP-1 levels were measured with an enzyme-linked immunosorbent assay, and the values were compared between OPMD and OSCC patients. Furthermore, the association of plasma MMP-1 levels and clinicopathological characteristics/survival outcomes in OSCC patients was investigated. Results: Plasma MMP-1 levels were significantly higher in OSCC patients than in OPMD patients (p = 0.04). In the OSCC group, plasma MMP-1 levels were significantly higher in females, tumor depth ≥ 10 mm, advanced pT classification and advanced overall stage (p = 0.04, < 0.001, < 0.001, 0.002, respectively). Higher plasma MMP-1 levels were significantly associated with poorer overall, disease-specific, disease-free, locoregional recurrence-free and distant metastasis-free survival (p = 0.003, 0.02, 0.005, 0.01, 0.001, respectively). Multivariate analysis revealed that plasma MMP-1 levels were a significant predictor for overall, disease-free, and distant metastasis-free survival (p = 0.03, 0.02, and 0.010, respectively). Conclusion: Plasma MMP-1 levels are associated with more severe clinicopathological manifestations and can also be regarded as a significant prognostic factor for OSCC posttreatment outcomes.
- Subjects
SQUAMOUS cell carcinoma; ENZYME-linked immunosorbent assay; MATRIX metalloproteinases; BIOMARKERS; SURVIVAL rate
- Publication
Cancer Management & Research, 2022, Vol 14, p3459
- ISSN
1179-1322
- Publication type
Article
- DOI
10.2147/CMAR.S389742